News

51. Bora Pharmaceuticals Unveils Eye-Opening New Facility For Ophthalmic Manufacturing 7/31/2023

    Bora Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), is pleased to announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.

52. Advent Therapeutics Awarded $3M NIH Grant For Novel Neonatal Lung Therapy 7/18/2023

    Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

53. WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line At Wuxi City Site 7/17/2023

    WuXi STA – a global Contract Research, Development, and Manufacturing Organization (CRDMO) – launches a first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China.

54. Innovative Drug Formulations Make Medicines More Patient-Friendly: Aenova And Galvita Enter Strategic Partnership 7/13/2023

    The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health.

55. Race Executes Agreement With Ardena For GMP Manufacturing Of RC220 7/12/2023

    Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.

56. Strategic Partnership For Dose Counter Technology Production 7/11/2023

    Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart, a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. 

57. Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Pivotal Phase 3 Safety Trial For GTX-104 In aSAH Patients 7/10/2023

    Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104, today announced WuXi Clinical Development, Inc. ("WuXi Clinical"), a wholly owned subsidiary of WuXi AppTec, a global Contract Research Organization (CRO), will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion (IV) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH).

58. Meissa Vaccines Enters Into cGMP Manufacturing Agreement For Pediatric RSV Vaccine Candidate For Phase 2 Clinical Trials 6/28/2023

    Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced it has entered into a manufacturing agreement with Exothera S.A. (“Exothera”), a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO) delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

59. Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation For Clopidogrel That Received IND Approval 6/27/2023

    Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

60. Stevanato Group Presents Vertiva, A Versatile On-Body Delivery System Platform For A Wide Range Of Injectable Therapies And For Large Delivery Volumes (Up To 100mL) 6/12/2023

    Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.